AMAG Pharmaceuticals, Inc. (AMAG) Tops Q2 EPS by 2c

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $24.8 million versus the consensus estimate of $23.4 million.

"Based on our commercial success in the first half of 2014, I am pleased to report that we are in a position to increase our sales guidance for the full year of 2014," said William Heiden, president and chief executive officer of AMAG. "Solid commercial execution has enabled Feraheme to capture market share from other IV iron products and drive overall market growth, setting a new record for Feraheme quarterly sales. We have also seen a steady growth trajectory for physician demand of MuGard in 2014 and continue to execute well on strategies to increase MuGard revenues."

For earnings history and earnings-related data on AMAG Pharmaceuticals, Inc. (AMAG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c